Reata Pharmaceuticals (NASDAQ:RETA) was having a terrible Tuesday, with its stock trading down by nearly 17% in late afternoon action. It scored earnings beats in its second quarter, but there was one notable cause for concern.
After market hours on Monday, Reata published its second-quarter earnings. Revenue for the developer of drugs for rare diseases fell by 28% on a year-over-year basis to $2.22 million. Net loss for the period was $72.7 million, or $2 per share, a bit deeper than the year-ago deficit of $67.6 million.
On average, though, prognosticators following the biotech were expecting worse. The average analyst projection for revenue was $1.25 million, and for per-share net loss it was $2.08.
That apparently positive news was tempered by Reata’s accompanying update on its current clinical programs. While its omaveloxolone, a drug aimed at genetic disorder Friedreich’s Ataxia, will happily be the subject of a pre-New Drug Application meeting with the Food and Drug Administration at some point this quarter.
On the down side, Reata said that regarding bardoxolone — targeting a form of chronic kidney disease (CKD) — “the FDA identified four significant clinical and statistical review issues for us to address.”
This doesn’t necessarily mean the end of bardoxolone; Reata believes that “each of the identified issues is addressable with additional data and analyses.” Still, biotech investors are a grumpy bunch when a program triggers regulatory concern. Perhaps, then, this gives some room for Reata bulls to invest in the company on the cheap.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
View more information: https://www.fool.com/investing/2021/08/10/why-reata-pharmaceuticals-is-diving-today-despite/